Body
Use of antipsychotic medications was associated with an increased risk of head injuries in a study of individuals with Alzheimer's disease. The findings are published in the Journal of the American Geriatrics Society.
HOUSTON -- A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein (CREBBP). Mutations of CREBBP are frequently found in follicular lymphoma and diffuse large B-cell lymphomas (DLBCL), and allow malignant cells to hide from the immune system.
Aurora, Colo. (Jan. 8, 2020) - The Lancet Infectious Diseases recently published the results of an observational study led by researchers on Children's Hospital Colorado Infectious Disease and Neurology teams, along with counterparts at the Centers for Disease Control and Colorado Department of Public Health and Environment. The study was conducted from March 1 to November 30, 2018, and led to a discovery of the largest outbreak of enterovirus A71 (EV-A71) in the United States.
Washington (January 8, 2020) - Parents who worry their child with celiac disease may be exposed to gluten at school might be able to strike two common school substances -- Play Doh and dry, uncooked pasta -- from the exposure risk list, as long as children don't consume them.
Starting HIV antiretroviral therapy (ART) within hours of birth has been hypothesized to have positive effects raising the possibility of remission in some children with HIV. To test the hypothesis, researchers at Columbia Mailman School of Public Health and Columbia University Irving Medical Center designed a trial in a group of newborns with HIV who started ART within 14 days of birth. The results showed that about 75 percent of infants attained viral suppression on ART; but only 52 percent attained and sustained viral suppression on ART.
What The Study Did: This randomized clinical trial examined the effects of daily folic acid and zinc supplementation in men on semen quality and live births among 2,300 couples planning infertility treatment.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Authors: Enrique F. Schisterman, Ph.D., of the Eunice Kennedy Shriver National Institute of Child Health and Human Development in Bethesda, Maryland, is the corresponding author.
What The Study Did: This study assessed changes between 2008 and 2018 in the rate of cesarean deliveries in China.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Authors: Jian-meng Liu, Ph.D., of the Peking University Health Science Center in Beijing, is the corresponding author.
(doi:10.1001/jama.2019.17595)
CHAMPAIGN, Ill. -- Scientists have developed new drug compounds that thwart the pro-cancer activity of FOXM1, a transcription factor that regulates the activity of dozens of genes. The new compounds suppress tumor growth in human cells and in mouse models of several types of human breast cancer.
The researchers report their findings in the journal NPJ Breast Cancer.
A risk-management program set up in 2012 by the U.S. Food and Drug Administration to curb improper prescribing of extended-release and long-acting opioids may not have been effective because of shortcomings in the program's design and execution, according to a paper from researchers at the Johns Hopkins Bloomberg School of Public Health. Extended-release and long-acting opioids, which include oxycontin, account for a significant proportion of the prescription opioid market and are among the most misused.
New Rochelle, NY, January 7, 2020--In a radical new approach to treat cocaine addition, researchers at the Mayo Clinic are seeking approval for first-in-human studies of a single-dose gene therapy. To support the safety and efficacy of this approach they have demonstrated the successful delivery of a gene coding for an enzyme that metabolizes cocaine into harmless byproducts in mice. The study is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
London, UK: A meta-analysis published in the journal Cephalalgia, the official journal of the International Headache Society, highlights the predictors of chronic migraine. The study, entitled "Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies", was coordinated by Dr. Dawn Buse, from the Department of Neurology at Albert Einstein College of Medicine, New York, USA.
ALEXANDRIA, VA - The American Academy of Otolaryngology-Head and Neck Surgery Foundation published the Clinical Practice Guideline: Nosebleed (Epistaxis) today in Otolaryngology-Head and Neck Surgery. A nosebleed is a common medical condition that occurs at some point in at least 60 percent of people in the United States.
'Are we waiting long enough?' Study raises questions on timing of intracranial pressure measurements
January 7, 2020 - Careful monitoring of pressure within the skull (intracranial pressure, or ICP) is crucial for some neurocritical care patients. But current procedures for measuring ICP via an external ventricular drain (EVD) may not leave enough time for accurate ICP readings, reports a study in the Journal of Neuroscience Nursing (JNN), official journal of the
A single dose of an antibody-based treatment can prevent HIV transmission from mother to baby, new nonhuman primate research suggests for the first time. The findings are being published in the journal Nature Communications.
When that single dose is given is key, however. The study found rhesus macaque newborns did not develop the monkey form of HIV, called SHIV, when they received a combination of two antibodies 30 hours after being exposed to the virus.
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology. The publication is for 'Arm Q,' which is one of nearly 40 single-arm phase two treatments in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) trial. NCI-MATCH is being co-led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), part of the National Institutes of Health.